Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — lamotrigine

Psych CASC / OSCE · Psychopharmacology — lamotrigine

Explaining lamotrigine titration and rash safety (CASC)

CASC-style communication station: polarity rationale, slow titration with valproate, OCP interaction, balanced SJS counselling without false reassurance or terror, written safety plan.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 30-year-old with bipolar I depression-predominant course is offered lamotrigine. She is on valproate after a recent manic episode and takes a combined oral contraceptive. She has read online about 'Stevens-Johnson syndrome' and is terrified, but also desperate to prevent another six-month depression.

Station instructions (candidate)

You have 7 minutes. Explain why lamotrigine fits depression-pole prevention, how you will start it slowly because she is on valproate, how her combined pill affects levels, and which rash symptoms mean stop-and-seek-help. Balance honesty about rare serious rash against the cost of untreated bipolar depression. Do not guarantee zero risk. Do not dismiss fear. Do not invent exact national tablet strengths if unsure — explain principles and that the written schedule follows product guidance.[1][2][3][4]

Marking domains

Agenda setting and empathy; accurate plain-language polarity rationale; explanation of slow titration and why valproate changes the schedule; OCP interaction counselling; clear red-flag rash teaching; collaborative plan with written instructions and review dates; hope without hype grounded in maintenance evidence.[1][2][3][4][5][6]

Model communication map

  1. Open: acknowledge fear about Stevens-Johnson syndrome; name shared goals (fewer long depressions, safety).[4]
  2. Why this medicine: her pattern is depression-heavy bipolar illness; lamotrigine has evidence for helping prevent depressive return after mood stabilisation — not a quick mania tablet.[1][6]
  3. Why so slow: serious rash risk is reduced by starting low and increasing slowly; because valproate raises lamotrigine levels, her schedule will be even more careful than standard.[2][5]
  4. The pill: combined contraceptives can lower lamotrigine levels; we account for that and must know if she starts or stops the pill later.[3]
  5. Red flags: mouth/eye sores, blistering, peeling, fever with spreading rash → stop the medicine and seek urgent care the same day. Mild spots still deserve a same-day call if she is unsure.[4]
  6. Close: written titration card, emergency contacts, next review, questions.[5]

Common fails

  • Dismissing SJS as "internet nonsense" without a safety plan.[4]
  • Using a fast load because "she is depressed now."[5]
  • Ignoring valproate or the OCP.[2][3]
  • Promising cure or zero rash risk.[1][4]
  • Forgetting written instructions and follow-up.[5]

References

  1. [1]Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiatry, 2004.PMID 15096085
  2. [2]Yuen AW, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism Br J Clin Pharmacol, 1992.PMID 1524964
  3. [3]Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels Neurology, 2003.PMID 12939444
  4. [4]Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children Epilepsia, 1999.PMID 10403224
  5. [5]Messenheimer JA, Guberman AH Rash with lamotrigine: dosing guidelines Epilepsia, 2000.PMID 10756418
  6. [6]Geddes JR, Calabrese JR, Goodwin GM Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Br J Psychiatry, 2009.PMID 19118318